爱豆传媒

(Corporate Philosophy)

• Article 2.

  (1) The Company’s Corporate Philosophy is to give first thought to patients and their families, and to increase the benefits that health care provides to them. Under this Philosophy, the Company endeavors to become a human health care (hhc) company.

  <New>

    

    

  (2) The Company’s mission is the enhancement of patient satisfaction. The Company believes that revenues and earnings will be generated by fulfilling this mission. The Company places importance on this sequence of placing the mission before the ensuing results.

    

    

    
      

  (3) The Company strives to fulfill its social responsibilities by positioning compliance (i.e., the observance of legal and ethical standards) as the basis of all business activities.

  (4) The Company’s principal stakeholders are patients, customers, shareholders and employees. The Company endeavors to develop and maintain a good relationship with stakeholders and to enhance the value of their stake through:

  1.  Satisfying unmet medical needs, ensuring a stable supply of high-quality products, and providing useful information on subjects including drug safety and efficacy;

    

   <New>
    
    

  2.  Timely disclosure of corporate management information, enhancement of corporate value, and a positive return to shareholders; and
  
    

  3. Ensuring stable employment, offering challenging and fulfilling duties, and providing full opportunities for the development of employees’ capabilities.

• Article 2.

  (1) The Company’s Corporate Philosophy is to give first thought to patients and the general public, and to increase the benefits that health care provides to them. Under this Philosophy, the Company endeavors to become a human health care (hhc) company.

  (2) The Company seeks to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities as a Japanese innovation company.

  (3) The Company’s mission is to increase the satisfaction of patients and the general public, and to empower people in the daily living and medical domains to realize their fullest life through an hhc ecosystem based on collaboration with other industries.
  The Company believes that revenues and earnings will be generated by fulfilling this mission. The Company places importance on this sequence of placing the mission before the ensuing results.

  (4) The Company strives to fulfill its social responsibilities by positioning compliance (i.e., the observance of legal and ethical standards) as the basis of all business activities.

  (5) The Company’s principal stakeholders are patients and the general public, shareholders and employees. The Company endeavors to develop and maintain a good relationship with stakeholders and to enhance the value of their stake through:

  1. Satisfying unmet medical needs, raising awareness of illnesses and providing information and services that help prevent them, ensuring a stable supply of high-quality products, and providing useful information on subjects including drug safety and efficacy;

  2. Contributing to a sustainable society with a long-term perspective;

  3. Enhancement of common interests of shareholders and long-term corporate value, a positive return to shareholders and timely disclosure of corporate management information; and

  4. Ensuring stable employment, respecting human rights and diversity, providing full opportunities for growth to support self-fulfillment, and creating an employee-friendly environment.

(Convocation)

• Article 13.

  (1) (Omitted)

  (2) (Omitted)

  (3) General Meetings of Shareholders shall be held at a place located in Tokyo.

(Convocation)

• Article 13.

  (1) (Current)

  (2) (Current)

  (3) General Meetings of Shareholders shall be held at a place located in Tokyo.
  However, it shall be possible to change the location of the venue if it is deemed to be difficult to hold the meeting in Tokyo.

(Internet disclosure of reference documents, etc. and deemed provision thereof)

• Article 15.

  In convening a General Meeting of Shareholders, the Company shall be deemed to have provided the shareholders with the information that must be mentioned or displayed in the reference documents of a General Meeting of Shareholders, business reports, financial statements and consolidated financial documents by disclosing such information via the Internet pursuant to the regulations issued by the Ministry of Justice.

<Delete>

• Article 15.

  (1) When convening a General Meeting of Shareholders, the Company shall implement measures to provide the information contained in General Meeting of Shareholders Reference Materials, etc., electronically.

  (2) The Company may choose not to include all or part of the matters for which electronic provision measures are implemented, which have been stipulated by Ordinance of the Ministry of Justice, in written documents provided to shareholders who have requested them by the record date for voting rights. 

(Supplementary Provisions)

1. Removal of Article 15 of the current Articles of Incorporation (Internet disclosure of reference materials, etc., and deemed provision thereof) and proposed amendments establishing Article 15 (Electronic Provision Measures, etc.) shall take effect as of September 1, 2022.

2. Notwithstanding the stipulations of the preceding Paragraph, the stipulations of Article 15 of the current Articles of Incorporation shall remain in effect for General Meetings of Shareholders held on or before the final day of February 2023.